KAT2B

Across TCGA pan-cancer cohorts, KAT2B mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of KAT2B’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where KAT2B mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types KAT2B is over-expressed in tumor, although a few such as LSCC and LUAD show the opposite, repressed pattern.

LSCC, LUAD, and PDAC are the cancer types where KAT2B tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in KAT2B mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Male	All	−0.400	<.001	8	view →
LUAD	Female	All	−0.389	<.001	8	view →
PDAC	All	II,III,IV	−0.814	<.001	7	view →
CCRCC	All	All	+0.309	.019	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

KAT2B–LSCC

Open the LSCC breakdown →